Interviews

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.

Discover groundbreaking advancements in GI cancer treatments from ASCO 2025, highlighting innovative therapies and improved patient outcomes.

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

Arturo Loaiza-Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment approach, combining chemotherapy and immunotherapy.

Michael Green, PhD, discusses a new method of assessing lymphoma subtypes utilizing the tumor microenvironment.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the phase 3 ATOMIC trial presented at the 2025 American Society of Clinical Oncology Annual Meeting.

AI streamlines patient identification for clinical trials, significantly reducing review time while maintaining high accuracy, transforming oncology workflows.

Christina Poh, MD, discusses the promising data supporting the chemotherapy-free combination of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Theresa Medina, MD, discusses the C-144-01 study of lifileucel in patients with advanced melanoma.

Arturo Loaiza-Bonilla, MD, MSEd, discusses the potential of disitamab vedotin, toripalimab, and chemotherapy/trastuzumab in first-line treatment.

Biren Saraiya, MD, discusses how he sees findings from the phase 3 AMPLITUDE trial being incorporated into clinical practice for the treatment of metastatic castration-sensitive prostate cancer.

Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

GLP-1 receptor agonists show promise in reducing cancer risk and enhancing early detection, highlighting the need for further research in oncology.

Dax Kurbegov, MD, discusses findings from the CORE-HH study that build on growing evidence to support the clinical feasibility of blood-based early detection tools.

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Pedro C. Barata, MD, MSc, discusses a typical process for an oncologist to patients who are newly diagnosed with metastatic hormone-sensitive prostate cancer.

Asciminib shows significant safety and efficacy advantages over nilotinib in treating newly diagnosed chronic myeloid leukemia, promising a new standard of care.

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.

Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical Oncology Annual Meeting: the AMPLITUDE trial.

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary disease.

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.